[Evaluation of the efficacy of a new antimycotic molecule for topical use: naftifine].

The antifungal efficacy and tolerability of naftifine (cream, gel, 1% solution), were tested in an open, mycologically controlled study in 29 patients (mean age 32.7 +/- 2.8 years; 15 males, 14 females) with dermatomycosis caused by dermatophytes and yeasts. Particularly, 16 patients were affected with Tinea corporis; 11 patients by Pityriasis Versicolor and 2 other by cutaneous candidiasis. The mean treatment period was 32.9 days in a range from 1 to 44 days. Only one patient, with cutaneous candidiasis dropped out on the first day, because of a primary irritative dermatitis. All the remaining patients (96.4%) were recovered, and the severity of clinical symptoms, particularly erythema and itching, showed a very rapid decline. Two weeks after the treatment, a relapse emerged from a fungal growth culture, only in 2 patients (6.8%) affected with Microsporum canis. Local side effects, mostly burning, were recorded in 2 patients (6.8%).